With guidance unchanged and no major catalysts near-term, the stock is likely range-bound. Key catalysts to watch: ZILRETTA shoulder OA Phase 3 topline (H2 2026) and PCRX-201 Phase 2 Part A readout. The aggressive buyback ($50M in Q1) provides a floor but does not offset declining GAAP earnings. Monitor for any guidance revision on the Q2 call.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $24.44entry
- T+1 · 7mo ago +1.02%α +1.36% · $24.69
- T+5 · 6mo ago −5.28%α −7.63% · $23.15
- T+20 · 6mo ago −6.06%α −11.32% · $22.96
- T+60 · 4mo ago +9.70%α +6.63% · $26.81
Price Chart
How similar events traded
Executive Summary
Pacira BioSciences reported Q1 2026 revenue of $177.4M (+5% YoY) and GAAP EPS of $0.07, down from $0.10 a year ago. Non-GAAP EPS was $0.60, roughly in line with the $0.62 Street consensus from the prior quarter. The company reiterated full-year 2026 guidance, completed enrollment in a pivotal ZILRETTA shoulder OA study, and repurchased $50M in stock. Results were solid but not exceptional, revenue growth was steady, but GAAP profitability declined and guidance was unchanged.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue of $177.4M, up 5% YoY from $168.9M
- GAAP net income of $2.9M ($0.07 per share) vs $4.8M ($0.10) in Q1 2025
- Non-GAAP net income of $24.5M ($0.60 per share) vs $30.0M ($0.62) in Q1 2025
- Adjusted EBITDA of $40.2M vs $44.1M in Q1 2025
- EXPAREL sales $143.3M (+5% YoY); ZILRETTA $26.8M (+15%); iovera $6.2M (+21%)
- Repurchased 2.2M shares for $50M at avg $22.28; $100M remaining on authorization
- Full-year 2026 guidance reiterated: total revenue $745M-$770M, EXPAREL $600M-$620M
- Completed enrollment in Phase 3 ZILRETTA shoulder OA study; topline expected by year-end
- Cash and investments of $202.2M at quarter-end
Financial Impact
Revenue grew 5% YoY but GAAP net income fell 39% YoY; non-GAAP EPS roughly flat vs prior year
Risk Factors
- GAAP net income declining YoY despite revenue growth, operating expenses rising faster
- EXPAREL faces generic competition risk and GPO discounting pressure
- Pipeline catalysts (ZILRETTA shoulder, PCRX-201) are binary and may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-028854 |
| Document: pcrx-20260430.htm | 0001628280-26-028854 |
| Document: 0001628280-26-028854-index-headers.html | 0001628280-26-028854 |
| Document: 0001628280-26-028854-index.html | 0001628280-26-028854 |
| Document: 0001628280-26-028854.txt | 0001628280-26-028854 |
| 8-K Data (Synthetic) | 0001628280-26-028854 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers